skip to content

Cambridge Immunology Network



I lead a team within Oncology R&D at MedImmune, which is the global biologics arm of AstraZeneca. The focus of my work is on antibody therapeutics that enhance immune responses to cancer, primarily through activation of T cells. I work on a range of programs from early target assessment through to clinical development.



Key publications: 


Hooijkaas A, Gadiot J, Morrow M, Stewart R, Schumacher T, Blank CU Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology. 2012 Aug 1;1(5):609-617.

Stewart R, Thom G, Levens M, Güler-Gane G, Holgate R, Rudd PM, Webster C, Jermutus L, Lund J. A variant human IgG1-Fc mediates improved ADCC.

Protein Eng Des Sel. 2011 Sep;24(9):671-8.






Bornstein GG, Quéva C, Tabrizi M, van Abbema A, Chavez C, Wang P, Foord O, Ahluwalia K, Laing N, Raja S, Wen S, Green LL, Yang X, Webster C, Stewart R, Blakey D. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs. 2010 Oct;28(5):561-74.



Stewart R, Wei W, Challa A, Armitage RJ, Arrand JR, Rowe M, Young LS, Eliopoulos A, Gordon J. CD154 tone sets the signaling pathways and transcriptome generated in model CD40-pluricompetent L3055 Burkitt's lymphoma cells. J Immunol. 2007 Sep 1;179(5):2705-12.


Dr Ross   Stewart
Not available for consultancy


Person keywords: 
B cells